This study was presented in part at the 2012 Annual Meeting of the American Epilepsy Society in San Diego, CA.
Full-Length Original Research
Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study
Article first published online: 12 JUN 2013
Wiley Periodicals, Inc. © 2013 International League Against Epilepsy
Volume 54, Issue 8, pages 1498–1503, August 2013
How to Cite
Gaspard, N., Foreman, B., Judd, L. M., Brenton, J. N., Nathan, B. R., McCoy, B. M., Al-Otaibi, A., Kilbride, R., Fernández, I. S., Mendoza, L., Samuel, S., Zakaria, A., Kalamangalam, G. P., Legros, B., Szaflarski, J. P., Loddenkemper, T., Hahn, C. D., Goodkin, H. P., Claassen, J., Hirsch, L. J., LaRoche, S. M. (2013), Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study. Epilepsia, 54: 1498–1503. doi: 10.1111/epi.12247
- Issue published online: 30 JUL 2013
- Article first published online: 12 JUN 2013
- Manuscript Accepted: 9 MAY 2013
- Pfizer's Medical and Academic Partnerships Program
- SickKids Foundation
- Fundación Alfonso Martín Escudero
- UCB Pharma
- American Academy of Neurology
- David-Phinney Foundation/Sunflower Revolution
- University of Cincinnati Research Council
- Canadian Institutes of Health Research
- PSI Foundation
|epi12247-sup-0001-TableS1-S4.docx||Word document||77K|| |
Table S1. Details of subject enrollment by center.
Table S2. Treatments used for the treatment of RSE.
Table S3. Determinants of ketamine efficacy in nonanoxic cases (N = 53 episodes).
Table S4. Adverse events occurring prior to and during ketamine infusion.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.